BLU-222, an investigational, oral, potent, and highly selective CDK2 inhibitor (CDK2i), as monotherapy in patients (pts) with advanced solid tumors and in combination with ribociclib (RIBO) and ...
Neuroblastoma is the most common tumor among children under a year of age, and while in its gentlest form neuroblastoma can regress on its own, it can also take an aggressive form, with high-risk ...
Researchers in Japan found that lower plasma copper levels and reduced white matter volume in individuals with autism ...
Prognostic value of hedgehog signaling in cervical carcinoma. Background: Although improvements in the treatment of ovarian cancer have increased the global prognosis, the metastatic disease is still ...
A newly published study in Genes & Diseases highlights the crucial role of the mammalian target of rapamycin (mTOR) pathway in the progression of diabetic nephropathy (DN) and explores its potential ...
The NUZ-001 arm of the HEALEY ALS trial is expanding enrollment to 240 participants. NUZ-001 is an experimental ALS therapy ...
Highlights: Montara Therapeutics awarded non-dilutive funding grant from The Michael J. Fox Foundation (MJFF) to advance a BrainOnly™ therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results